Board of Directors
ROGER H. KIMMEL is currently Chairman of the Board
of Endo and is chairman of Endo's Nominating & Governance Committee and a member
of Endo's Audit Committee and Transactions Committee. Mr. Kimmel became Chairman
of the Board upon the retirement of founder Carol A. Ammon on May 30, 2007. Mr.
Kimmel had been a Director of Algos Pharmaceutical Corporation since July 1996 and
became a Director of Endo following its merger with Algos in July 2000. Mr. Kimmel
has been Vice Chairman of Rothschild Inc., an investment banking firm, since January
2001. Previously, Mr. Kimmel was a partner of the law firm Latham & Watkins for
more than five years. Mr. Kimmel is also a director of PG&E Corporation and Schiff
Nutrition International, Inc. Mr. Kimmel has been Chairman of the Board of Trustees
of the University of Virginia Law School Foundation (not-for-profit) since January
2009. He has been a public speaker on corporate governance issues and private equity
transactions.
JOHN J. DELUCCA has been a member of the Board of
Directors since 2006 and is the Chairman of Endo's Audit Committee and is a member
of Endo's Compensation Committee. Mr. Delucca was Executive Vice President and Chief
Financial Officer of the REL Consultancy Group, a business consulting firm, until
his retirement in 2004. Prior to that, he served as Chief Financial Officer and
Executive Vice President, Finance & Administration, of Coty, Inc., a fragrance and
beauty products company, from 1999 to 2002. From 1993 to 1999, he was Senior Vice
President and Treasurer of RJR Nabisco, Inc. During his career, he also served in
executive positions for Hascoe Associates, Inc., The Lexington Group, the Trump
Group, International Controls Corp., and Textron, Inc. Mr. Delucca is currently
a Non-Executive Director and chairs the Audit Committees of The Elliot Company,
an industrial manufacturer. He also serves as a Non-Executive Director and member
of the Audit Committee and Governance and Nominating Committee of Tier Technologies,
Inc., a publicly traded payment solutions company. Mr. Delucca also serves as a
Non-Executive Director and chairs the Audit Committee and a member of the Compensation
Committee of Elster Group, a publicly traded company providing integrated metering
and utilization solutions to the gas, electricity and water industries.
DAVID P. HOLVECK is President, Chief Executive Officer and a Director of Endo. Prior to joining Endo in April 2008, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson, a diversified healthcare company, since 2004. Mr. Holveck joined Johnson & Johnson as a Company Group Chairman in 1999, following the acquisition of Centocor, Inc., a biotechnology company, by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc. at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for The Fund for West Chester University, as well as the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), the University City Science Center, and the Kimmel Center. Mr. Holveck’s knowledge of the Company, its operations and the evolving healthcare environment is valuable to the Board of Directors in evaluating and directing the Company’s future. Through his service on the boards of directors of other organizations as well as his prior senior executive positions at global pharmaceutical and healthcare product companies, Mr. Holveck has developed extensive knowledge of operational leadership, risk oversight and management, as well as the pharmaceutical and device industries.
NANCY J. HUTSON, Ph.D. has been a member of the Board
of Directors since 2009 and is a member of Endo's Compensation Committee, Nominating
& Governance Committee and Transactions Committee. Dr. Hutson retired from Pfizer,
Inc. in 2006 after spending 25 years in various research and leadership positions,
most recently serving as Senior Vice President, Pfizer Global Research and Development
and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories,
the largest R&D site of any pharmaceutical company. At Pfizer, she led 4,500 colleagues
(primarily scientists) and managed a budget in excess of $1 billion. She currently
is a director of Cubist Pharmaceuticals, Inc. and Inspire Pharmaceuticals, Inc.,
and serves on the board of Planned Parenthood of Connecticut. Dr. Hutson owns and
operates Standing Stones Farm in Ledyard, CT which is dedicated to supporting the
equestrian sport of dressage.
MICHAEL HYATT is currently a Director of Endo and
is Chairman of Endo's Transactions Committee and a member of Endo's Nominating &
Governance Committee. Mr. Hyatt had been a director of Algos Pharmaceutical Corporation
since November 1996 and became a director of Endo following its merger with Algos
in July 2000. Mr. Hyatt is currently a senior advisor to Irving Place Capital, a
leading institutional private equity firm focused on making equity investments in
middle-market companies. Until 2008, Mr. Hyatt was a Senior Managing Director of
Bear Stearns & Co., Inc. In April 2009, Mr. Hyatt was appointed a director of Schiff
Nutrition International, Inc., a publicly traded manufacturer and marketer of nutritional
supplements.
WILLIAM P. MONTAGUE has been a member of the Board of Directors since 2009 and is a member of Endo's Audit Committee, Nominating & Governance Committee and Transactions Committee. Mr. Montague was Chief Executive Officer and Director of Mark IV Industries, Inc., a leading global diversified manufacturer of highly engineered systems and components for transportation infrastructure, vehicles and equipment, from November 2004 until his retirement on July 31, 2008 and as Director from March 1996. He joined Mark IV Industries in April 1972 as Treasurer/Controller, serving as Vice President of Finance from May 1974 to February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996 and then as President from March 1996 to November 2004. Mr. Montague is also a director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets and in December of 2010, Mr. Montague became a director of International Imaging Materials, Inc., a privately held company that manufactures and sells a variety of thermal transfer ribbons and certain inks.
DAVID B. NASH, M.D., M.B.A. was appointed to the Board in March 2011 and is a member of Endo’s Compensation Committee. He is the founding dean of the Jefferson School of Population Health, located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 to 2008. Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in more than 100 articles in major journals. Dr. Nash serves on the Board of Directors of Humana Inc., one of the nation’s largest publicly traded health and supplemental benefits companies. Dr. Nash also has served as a member of the Board of Trustees of Catholic Healthcare Partners in Cincinnati, Ohio. The Board believes that Dr. Nash brings a unique and value-added set of attributes that enhance the Company's ability to help people achieve lifelong well-being. Dr. Nash is a widely recognized innovator in an emerging medical discipline that unites population health, health policy, and individual health.
JOSEPH C. SCODARI has been a member of the Board
of Directors since 2008 and is Chairman of Endo's Compensation Committee and is
a member of Endo's Transactions Committee. Mr. Scodari was Worldwide Chairman, Pharmaceuticals
Group, of Johnson & Johnson, a diversified healthcare company, and a Member of Johnson
& Johnson's Executive Committee from March 1, 2005 until March 1, 2008. He joined
Johnson & Johnson in 1999 as President of Centocor, Inc., a biotechnology company,
when Johnson & Johnson acquired Centocor. At the time of that acquisition, he had
been the President and Chief Operating Officer of Centocor and a member of Centocor's
Board of Directors since December 1997. In 2001, he was named Johnson & Johnson's
Company Group Chairman for the North American pharmaceutical business, and became
a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee. In
2003, Mr. Scodari was named Johnson & Johnson Company Group Chairman, Global Biopharmaceutical
Business. Mr. Scodari is a director of Covance Inc., a publicly traded drug development
service company, and Actelion Pharmaceuticals Ltd., a publicly traded Swiss biopharmaceutical
company. Prior to joining Centocor, Mr. Scodari served in various senior leadership
roles at Sterling Drug and later, Rhone-Poulenc Rorer.
WILLIAM F. SPENGLER has been a member of the Board
of Directors since 2008 and is a member of Endo's Audit Committee and Compensation
Committee. Effective November 15, 2010, Mr. Spengler was appointed President of
ChromaDex Corporation, a publicly traded company that is a leader in the development
of phytochemical and botanical reference standards and that discovers, develops
and markets novel, natural ingredients that fill unmet needs for healthy dietary
supplements, foods, beverages, cosmetics and pharmaceuticals. From July 2008 until
November 2010, Mr. Spengler served as Executive Vice President and Chief Financial
Officer of Smith & Wesson Holding Corporation, a global leader in safety, security,
protection and sport. Until March 2008, he was Executive Senior Vice President and
Chief Financial Officer at MGI Pharmaceuticals Inc., an oncology- and acute care-
focused biopharmaceutical company, where he had worked since 2005. Prior to joining
MGI Pharma, Mr. Spengler was Executive Vice President and Chief Financial Officer
at Guilford Pharmaceuticals Inc., a bioscience company, from July 2004 to October
2005. From 2002 to 2004, Mr. Spengler served as President, Chief Operating Officer
and Director of Osteoimplant Technology, Inc., an orthopedic products company. Mr.
Spengler was previously a Vice President of Finance at Black & Decker, and prior
to that spent 14 years in various finance, planning and business development positions
at Bristol Myers Squibb.
